Thyroid-Stimulating Hormone Receptor Antibody Assays: Recommendation for Correct Interpretation of Results in Graves Disease

Massart, Catherine; d’Herbomez, Michèle

doi:10.1373/clinchem.2013.202747

Cited by 4 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Particularly, because development of anti-GFAP IgG auto-antibodies was suggested to be significant within only four days following traumatic brain injury (Zhang et al, 2014). There is a need to adopt the same rigorous methodological approach as for other auto-antibodies (Massart and d'Herbomez, 2013;Chantarangkul et al, 2013). Post-translational modifications of GFAP epitopes may also be important.…”

Section: Gfap Auto-antibodiesmentioning

confidence: 99%

Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease

Petzold

2015

Brain Research

View full text Add to dashboard Cite

This review on the role of glial fibrillary acidic protein (GFAP) as a biomarker for astroglial pathology in neurological diseases provides background to protein synthesis, assembly, function and degeneration. Qualitative and quantitative analytical techniques for the investigation of human tissue and biological fluid samples are discussed including partial lack of parallelism and multiplexing capabilities. Pathological implications are reviewed in view of immunocytochemical, cell-culture and genetic findings. Particular emphasis is given to neurodegeneration related to autoimmune astrocytopathies and to genetic gain of function mutations. The current literature on body fluid levels of GFAP in human disease is summarised and illustrated by disease specific meta-analyses. In addition to the role of GFAP as a diagnostic biomarker for chronic disease, there are important data on the prognostic value for acute conditions. The published evidence permits to classify the dominant GFAP signatures in biological fluids. This classification may serve as a template for supporting diagnostic criteria of autoimmune astrocytopathies, monitoring disease progression in toxic gain of function mutations, clinical treatment trials (secondary outcome and toxicity biomarker) and provide prognostic information in neurocritical care if used within well defined time-frames.

show abstract

Section: Gfap Auto-antibodiesmentioning

confidence: 99%

Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease

Petzold

2015

Brain Research

View full text Add to dashboard Cite

show abstract

Diagnostic procedure in suspected Graves’ disease

Goichot

Leenhardt²,

Massart

et al. 2018

Annales d'Endocrinologie

View full text Add to dashboard Cite

Laboratory Investigations for Diagnosis of Autoimmune and Inflammatory Periocular Disease: Part I

Srinivasan

Kleinberg

Murchison

et al. 2016

Ophthalmic Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

This review covers important laboratory serological investigations specific to entities routinely encountered by orbitologists. The technique, parameters measured, and clinical importance of each of these laboratory tests are discussed in detail. Due to the extensive nature of the topic, the review has been split into 2 parts. Part I covers thyroid eye disease, IgG4-related disease, and myasthenia gravis. In part II of the review, sarcoidosis, vasculitis, Sjögren syndrome, and giant cell arteritis will be discussed.

show abstract

Thyroid-Stimulating Hormone Receptor Antibody Assays: Recommendation for Correct Interpretation of Results in Graves Disease

Cited by 4 publications

References 5 publications

Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease

Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease

Diagnostic procedure in suspected Graves’ disease

Laboratory Investigations for Diagnosis of Autoimmune and Inflammatory Periocular Disease: Part I

Contact Info

Product

Resources

About